moxifloxacin has been researched along with nsc 663284 in 1 studies
Studies (moxifloxacin) | Trials (moxifloxacin) | Recent Studies (post-2010) (moxifloxacin) | Studies (nsc 663284) | Trials (nsc 663284) | Recent Studies (post-2010) (nsc 663284) |
---|---|---|---|---|---|
3,157 | 552 | 1,690 | 28 | 0 | 20 |
Protein | Taxonomy | moxifloxacin (IC50) | nsc 663284 (IC50) |
---|---|---|---|
Replicase polyprotein 1ab | Severe acute respiratory syndrome-related coronavirus | 2.63 | |
Replicase polyprotein 1ab | Severe acute respiratory syndrome coronavirus 2 | 2.63 | |
M-phase inducer phosphatase 1 | Homo sapiens (human) | 1.015 | |
M-phase inducer phosphatase 2 | Homo sapiens (human) | 0.77 | |
M-phase inducer phosphatase 3 | Homo sapiens (human) | 0.505 | |
Dual specificity protein phosphatase 3 | Homo sapiens (human) | 4 | |
N-lysine methyltransferase KMT5A | Homo sapiens (human) | 0.21 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 1 (100.00) | 2.80 |
Authors | Studies |
---|---|
Chen, J; Gao, K; Huang, F; Tepe, JJ; Wang, R; Wei, GW | 1 |
1 other study(ies) available for moxifloxacin and nsc 663284
Article | Year |
---|---|
Perspectives on SARS-CoV-2 Main Protease Inhibitors.
Topics: Antiviral Agents; Coronavirus 3C Proteases; Humans; Protease Inhibitors | 2021 |